I am writing to you today to formally request details regarding Growth Hormone use and policies within your organisation.
1. For each of the listed licensed Somatropin preparations in the table below (Table 1.1Somatropin Table) please provide information on:
(Please provide answers in the table provided)
i) Are there any restrictions to the prescribing of each preparation?
There are no restrictions in place on choice of product by the CCG but initiated by the specialist not primary care and continued in line with local shared care guidelines.
IF YES – Please state, where possible, the reason for the restriction and if the restriction applies to children (patients aged 18 or under)
ii) Are there any planned changes to these restrictions over the period of the rest of this financial year (2017/18) and 2018/19?
There are no planned changes. See below.
IF YES – please provide details of planned changes.
|If restricted, please state reason given.||Does this restriction apply to children (patients aged 18 or under)?||Are there any Planned changes to Restricted status?
If yes please provide details
Table 1.1. Somatropin Table
2. Please provide a copy of the latest written policy, protocol, pathways, shared care agreement or other literature outlining your organisation’s recommendations for the use of licensed Somatropin preparations in children (patients aged 18 or under) in line with NICE TA 188?
These can be found at the below links:
3. Are local policies for the use or restriction of licensed Somatropin preparations in patients aged 18 or under led by specialists in hospital or medicines optimisation/medicines management pharmacists within your organisation?
4. Does your organisation monitor adherence or have internal audits in place to monitor adherence in patients who have been prescribed a Somatropin product?
IF YES please provide details: